Analysts Issue Forecasts for LSTA Q1 Earnings

Lisata Therapeutics, Inc. (NASDAQ:LSTA) – Stock analysts at Brookline Capital Management issued their Q1 2025 earnings per share (EPS) estimates for Lisata Therapeutics in a research note issued on Wednesday, October 30th. Brookline Capital Management analyst K. Dolliver anticipates that the company will earn ($0.74) per share for the quarter. The consensus estimate for Lisata Therapeutics’ current full-year earnings is ($2.97) per share. Brookline Capital Management also issued estimates for Lisata Therapeutics’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.78) EPS and Q4 2025 earnings at ($0.75) EPS.

Lisata Therapeutics (NASDAQ:LSTA) last posted its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14. During the same period in the previous year, the business posted ($0.50) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Lisata Therapeutics in a report on Wednesday, September 18th.

Lisata Therapeutics Trading Up 11.7 %

Shares of LSTA opened at $3.16 on Thursday. Lisata Therapeutics has a 12 month low of $2.05 and a 12 month high of $3.83. The stock has a fifty day moving average price of $2.96 and a 200-day moving average price of $3.08. The firm has a market cap of $26.29 million, a PE ratio of -1.23 and a beta of 1.21.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP increased its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 8.94% of the stock is owned by institutional investors.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.